OnKure Therapeutics (OKUR) Competitors $2.40 0.00 (0.00%) Closing price 07/3/2025 01:33 PM EasternExtended Trading$2.40 0.00 (0.00%) As of 07/3/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OKUR vs. BYSI, NMRA, NKTX, FTLF, CRBU, IKT, CTNM, RAPT, GLSI, and TARAShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), FitLife Brands (FTLF), Caribou Biosciences (CRBU), Inhibikase Therapeutics (IKT), Contineum Therapeutics (CTNM), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. OnKure Therapeutics vs. Its Competitors BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Caribou Biosciences Inhibikase Therapeutics Contineum Therapeutics Rapt Therapeutics Greenwich LifeSciences Protara Therapeutics BeyondSpring (NASDAQ:BYSI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation. Which has more risk & volatility, BYSI or OKUR? BeyondSpring has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Do insiders & institutionals believe in BYSI or OKUR? 40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 2.3% of OnKure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is BYSI or OKUR more profitable? BeyondSpring's return on equity of 0.00% beat OnKure Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BeyondSpringN/A N/A N/A OnKure Therapeutics N/A -49.13%-45.72% Does the media refer more to BYSI or OKUR? In the previous week, BeyondSpring had 1 more articles in the media than OnKure Therapeutics. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for OnKure Therapeutics. BeyondSpring's average media sentiment score of 0.75 beat OnKure Therapeutics' score of 0.00 indicating that BeyondSpring is being referred to more favorably in the media. Company Overall Sentiment BeyondSpring Positive OnKure Therapeutics Neutral Do analysts rate BYSI or OKUR? OnKure Therapeutics has a consensus target price of $32.33, indicating a potential upside of 1,247.22%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33 Which has higher earnings and valuation, BYSI or OKUR? BeyondSpring has higher revenue and earnings than OnKure Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeyondSpring$1.75M51.84-$11.12MN/AN/AOnKure TherapeuticsN/AN/A-$52.67M-$5.26-0.46 SummaryBeyondSpring beats OnKure Therapeutics on 7 of the 13 factors compared between the two stocks. Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.15M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-0.4621.5627.4320.22Price / SalesN/A281.76416.87118.64Price / CashN/A42.7336.8958.07Price / Book0.317.518.035.67Net Income-$52.67M-$55.05M$3.18B$249.13M7 Day PerformanceN/A4.61%2.88%3.28%1 Month Performance-16.08%4.72%3.69%5.56%1 Year PerformanceN/A5.92%36.02%21.12% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics2.6976 of 5 stars$2.40flat$32.33+1,247.2%N/A$32.15MN/A-0.46N/ABYSIBeyondSpringN/A$2.74-13.6%N/A-8.9%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.5948 of 5 stars$0.75-5.1%$9.29+1,144.7%-91.7%$127.08MN/A-0.46108Gap UpNKTXNkarta2.273 of 5 stars$1.75-1.4%$14.33+721.4%-67.2%$125.60MN/A-1.16140FTLFFitLife Brands4.0619 of 5 stars$12.99-2.5%$20.50+57.8%-7.3%$125.09M$64.47M15.4620CRBUCaribou Biosciences2.3028 of 5 stars$1.32-1.5%$8.50+543.9%-15.0%$124.63M$9.99M-0.81100News CoverageAnalyst UpgradeIKTInhibikase Therapeutics1.3873 of 5 stars$1.66flat$6.50+291.6%+64.3%$123.41M$260K-0.626News CoverageCTNMContineum Therapeutics2.208 of 5 stars$4.12-13.4%$22.50+446.1%-80.2%$123.15M$50M-2.0931High Trading VolumeRAPTRapt Therapeutics4.1954 of 5 stars$7.44+0.1%$24.00+222.6%-62.7%$122.86M$1.53M-0.3980GLSIGreenwich LifeSciences1.5236 of 5 stars$8.76-1.6%$39.00+345.2%-39.9%$118.98MN/A-6.953TARAProtara Therapeutics1.7568 of 5 stars$2.88-5.6%$20.50+611.8%+38.4%$117.68MN/A-1.6730 Related Companies and Tools Related Companies BeyondSpring Alternatives Neumora Therapeutics Alternatives Nkarta Alternatives FitLife Brands Alternatives Caribou Biosciences Alternatives Inhibikase Therapeutics Alternatives Contineum Therapeutics Alternatives Rapt Therapeutics Alternatives Greenwich LifeSciences Alternatives Protara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKUR) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
